Thomas Wynn makes the leap out of the NIH and in­to a lead dis­cov­ery post for Pfiz­er

Thomas Wynn spent 26 years at the NIH, wrap­ping up re­cent­ly as a se­nior in­ves­ti­ga­tor and rec­og­nized ex­pert on im­munol­o­gy and fi­bro­sis. And he cites NIH chief Fran­cis Collins as a key fac­tor in his de­ci­sion to leave the Na­tion­al In­sti­tute of Al­ler­gy and In­fec­tious Dis­eases and head up ear­ly dis­cov­ery in Pfiz­er’s in­flam­ma­tion and im­munol­o­gy unit.

But in a good way.

Dur­ing Collins’ lengthy tenure at the NIH, says Wynn, the fed­er­al re­search in­sti­tute shift­ed fo­cus to be­come much more di­rect­ly in­volved with drug de­vel­op­ers. For Wynn, that meant two ac­tive projects with Pfiz­er where he was able to get a much bet­ter look at the phar­ma gi­ant’s re­search op­er­a­tions — and they got to know him as well.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.